DLA PIPER LLP (US)

Lobbying for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Trade association of innovative biopharmaceutical research companies.

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · District of Columbia · House · Senate · $60,000.00 income · posted Jan 20, 2026

Bills named in this filing 2

HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
S 832
EPIC Act of 2025

Lobbying activity 7

Budget/Appropriations

H.R. 1, One Big Beautiful Bill Act, provisions impacting pharmaceuticals.

Defense

National security issues related to pharmaceutical industry, including supply chain.

Trade (domestic/foreign)

Trade policies and agreements, including IP protections, and administrative tariff actions.

Intellectual property protections and enforcement. Biopharmaceutical patent policy.

Pharmacy

Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.

Health Issues

S. 832, EPIC Act of 2025.

Medicare/Medicaid

Medicare policies.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.